(Sharecast News) - Drugmaker GSK said on Friday that it had reached a settlement, alongside CureVac, to resolve long-running patent litigation with BioNTech and Pfizer over mRNA-based COVID-19 vaccines.
The agreement, which includes a substantial upfront payment of $370m and future royalties, marks a significant step in monetising GSK's intellectual property...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE